The state of Connecticut currently has 11 active clinical trials seeking participants for Parkinson's Disease research studies. These trials are conducted in various cities, including New Haven, Hartford, Farmington and Stamford.
Visualization of the STN and GPi for DBS
Recruiting
The purpose of the study is to determine if using SIS System for DBS planning results in less distance between the planned target location and the actual implanted lead location than DBS planning without SIS System.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: Hartford Hospital, Hartford, Connecticut
Conditions: Deep Brain Stimulation, Parkinson Disease
A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80
Recruiting
In this study, researchers will learn more about a study drug called BIIB122 in participants with early-stage Parkinson's disease (PD). In this study: Participants will take 225 milligrams (mg) of BIIB122 or a placebo as tablets by mouth. A placebo looks like the study drug but has no real medicine in it. Participants will take BIIB122 or placebo 1 time a day for up to a minimum of 48 weeks and a maximum of 144 weeks. Certain medications for PD will be allowed at enrollment for a subset of part... Read More
Gender:
All
Ages:
Between 30 years and 80 years
Trial Updated:
04/17/2024
Locations: Institute for Neurodegenerative Disorders (IND), New Haven, Connecticut
Conditions: Parkinson Disease
Neurologic Stem Cell Treatment Study
Recruiting
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http://mdstemcells.com/nest/
Gender:
All
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: MD Stem Cells, Westport, Connecticut
Conditions: Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders, Stroke, Traumatic Brain Injury, Cadasil, Chronic Traumatic Encephalopathy, Cerebral Infarction, Cerebral Ischemia, Cerebral Stroke, Cerebral Hemorrhage, Parkinson, Multi-System Degeneration, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, ALS, Amyotrophic Lateral Sclerosis, Neuropathy, Diabetic Neuropathies, Alzheimer Disease, Dementia, Frontotemporal Dementia, Lewy Body Disease, Cognitive Impairment, Lewy Body Variant of Alzheimer Disease
Intestinal Immunity in Neurologic Disease
Recruiting
The purpose of this study is to ascertain the functional profiles of the immune cells within the gastrointestinal tract and to determine how these cells contribute to autoimmune and neurologic diseases.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
03/22/2024
Locations: Yale MS Clinic, North Haven, Connecticut
Conditions: Multiple Sclerosis, Parkinson Disease, REM Sleep Behavior Disorder
Ketamine for the Treatment of Depression in Parkinson's Disease
Recruiting
The main purpose of this study is to examine the efficacy and safety of a repeated dosing ketamine infusion paradigm compared to placebo in individuals with PD. A subset of participants in each arm will undergo baseline and post-treatment PET and fMRI scans, to examine whether changes in synaptic density and reorganization of functional networks underlie ketamine's putative antidepressant effects in PD.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
02/14/2024
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Parkinson's Disease, Depression
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
Recruiting
The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls. The overall goal of PPMI is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.
Gender:
All
Ages:
30 years and above
Trial Updated:
12/13/2023
Locations: Institute For Neurodegenerative Disorders, New Haven, Connecticut
Conditions: Parkinson Disease
Peer Partners to Improve Physical Activity in Older Latino and Latina Adults With Parkinson's Disease.
Recruiting
The goal of this interventional study is to culturally adapt and determine feasibility of the peer partner training program and the peer-supported mobile health physical activity intervention in older Latin/Hispanic people with Parkinson's disease. The main question[s] it aims to answer are: What is the feasibility of the peer partner training program? What is the feasibility of the peer-supported mobile health physical activity intervention? What are the effects of the peer-supported mobile h... Read More
Gender:
All
Ages:
50 years and above
Trial Updated:
12/11/2023
Locations: University of Connecticut, Storrs, Connecticut
Conditions: Parkinson Disease
Cognitive Training in Parkinson's Disease
Recruiting
The purpose of this research study is to determine whether cognitive training will improve cognitive and brain functions in people with Parkinson's Disease (PD) during activities of daily living using cognitive evaluations and magnetic resonance imaging (MRI).
Gender:
All
Ages:
40 years and above
Trial Updated:
08/09/2023
Locations: Yale School of Medicine, New Haven, Connecticut
Conditions: Parkinson Disease
Trial of Parkinson's And Zoledronic Acid
Recruiting
This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 3500 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the Nationa... Read More
Gender:
All
Ages:
60 years and above
Trial Updated:
07/24/2023
Locations: University of Connecticut, Farmington, Connecticut +1 locations
Conditions: Parkinson Disease, Osteoporosis, Parkinsonism, Parkinson's Disease and Parkinsonism, Atypical Parkinsonism, Progressive Supranuclear Palsy, Multiple System Atrophy, Vascular Parkinsonism, Dementia With Lewy Bodies
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
Recruiting
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.
Gender:
All
Ages:
Between 30 years and 85 years
Trial Updated:
05/18/2022
Locations: Chase Family Movement Disorders Center - Vernon, Vernon, Connecticut
Conditions: Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein
Recruiting
The overall goal of this protocol is to: Evaluate [18F]UCB-2897 as an α-synuclein targeted radiopharmaceutical. The primary objective is: • Confirm a specific α -synuclein signal with [18F]UCB-2897 in participants with PD and/or MSA relative to healthy volunteers Secondary and exploratory objectives are: Determine the safety and tolerability of microdose [18F]UCB-2897 Evaluate preliminary dosimetry of [18F]UCB-2897 Additional exploratory objectives are: Determine the pharmacokinetics / me... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/01/2022
Locations: Invicro, New Haven, Connecticut
Conditions: Parkinson Disease, Multisystem Atrophy, Healthy Volunteer